DETAILED NOTES ON MBL77

For patients with symptomatic disease demanding therapy, ibrutinib is usually encouraged determined by four stage III randomized scientific trials comparing ibrutinib with chlorambucil monotherapy106 and various frequently applied CIT mixtures, particularly FCR, bendamustine furthermore rituximab and chlorambucil additionally obinutuzumab (ClbO).10